Grifols reported EUR114.37M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Arca Biopharma USD -29.58M 694K Dec/2025
aTyr Pharma USD -153K 24.71M Mar/2026
Bio Path USD -976K 3.62M Sep/2025
Brainstorm Cell Therapeutics USD -2.11M 797K Sep/2025
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cara Therapeutics USD -5.53M 621K Sep/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Grifols EUR 114.37M 34.03M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -36.08M 978K Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
TherapeuticsMD USD -1.09M 356K Jun/2024